J&J Medical Connect
Immunology
Immunology

Congress Materials – Congress of Clinical Rheumatology (CCR West 2026)

 

2026 Congress of Clinical Rheumatology | Sep 17-20 | Huntington Beach, CA

This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.

Analysis of Healthcare Utilization in Primary and Associated Sjögren’s Disease

Nora Sandorfi, Alexander Keenan, Elizabeth Adamson, Federico Zazzetti, Soumya D Chakravarty, Debbie Goldschmidt, Sakshi Sethi, Jessica Smith, Esen K. Akpek


This document will be available on Sep 17th 2026

Biomarker-Driven Insights to Clinical Response in DAHLIAS: a Nipocalimab Trial for Sjögren’s Disease

R. Hal Scofield, Hurley Li, Jacques-Eric Gottenberg, David Galbraith, Keying Ma, Lynn Tomsho, Chris Sisk, Kathleen Packard, Matthew J. Loza, Jonathan Hubbard, Kim Campbell, Dawn Waterworth, Sheng Gao, Carolyn Cuff, Steven Leonardo, Kathy Sivils


This document will be available on Sep 17th 2026

Clinically Relevant Anti-Vaccine and Virus Antibodies in Patients with Sjogren’s Disease Treated with Nipocalimab: Post-Hoc Analysis of the DAHLIAS Study

Faye Yu, Eugene Myshkin, Jonathan J. Hubbard, Kim Campbell, Matthew J. Loza, Kathleen Packard, Dessislava Dimitrova, Carolyn Cuff, Sheng Gao


This document will be available on Sep 17th 2026

Guselkumab Efficacy on MDA Components and Structural Damage Progression in Participants With Active and Erosive Psoriatic Arthritis

Laura C. Coates, Proton Rahman, Philip J. Mease, Oyediran Adelakun, Soumya D. Chakravarty, Alexa P. Kollmeier, Weihong Hu, Karissa Lozenski, Frank R. Wellborne, Arthur Kavanaugh, Christopher T. Ritchlin


This document will be available on Sep 17th 2026

Healthcare Resource Utilization Among Male Patients With Sjögren’s Disease

Nora Sandorfi, Alexander Keenan, Elizabeth Adamson, Federico Zazzetti, Soumya D Chakravarty, Debbie Goldschmidt, Sakshi Sethi, Jessica Smith, Esen K. Akpek


This document will be available on Sep 17th 2026

Nipocalimab for Warm Autoimmune Hemolytic Anemia: Results From the Phase 2/3 Randomized Double-Blind ENERGY Study

Bruno Fattizzo, Irina Murakhovskaya, Yasutaka Ueda, Doug Schlichting, Kristen Sweet, Michael Zelasky, Thanh Nguyen, Jagriti Craig, Jocelyn Leu, Leona Ling, Sheryl Pease, Cathye Shu


This document will be available on Sep 17th 2026

Nipocalimab in SLE: First-in-Class Efficacy and Safety Results Demonstrating Proof of Concept for FcRn Blockade From the Phase 2 JASMINE-SLE Study​

Richard A Furie, Ronald van Vollenhoven, Rafał Wojciechowski, Eric Morand, Guillermo J Pons-Estel, George A Karpouzas,6 Bart van Hartingsveldt, Robert W Hoffman, Terence Rooney, Sheng Gao, Robert Gordon, Kim Hung Lo, Thanh Nguyen, Jocelyn H Leu, Federico Zazzetti, Stanley J Marciniak, Steven Leonardo, Keying Ma, Kathy Sivils, Leonard Dragone, Loqmane Seridi, Linda Okonkwo, Erika Noss, Fang Liu-Walsh, Michelle Petri


This document will be available on Sep 17th 2026

Patient-Reported Outcomes Through 1 Year With Guselkumab in Participants With Active PsA and Inadequate Response to 1 Prior TNFi in SOLSTICE

Alexis Ogdie, Alice B. Gottlieb, Philip J. Mease, Joseph F. Merola, Elizabeth Adamson, Soumya D. Chakravarty, Yanli Wang, Fowzia Ibrahim, Kimberly Parnell Lafferty, Christopher T. Ritchlin, Jose U. Scher


This document will be available on Sep 17th 2026

Pregnancy outcomes in maternal exposure to guselkumab: Review of cases reported to the Company Global Safety Database

Uma Mahadevan, Millie Long, Mette Julsgaard, Connie Lin, Anja Geldhof, Mauricio Rosas Ballina, Hewei Li, Allison Hester, Javier P. Gisbert, María Chaparro


This document will be available on Sep 17th 2026

Structural Damage Progression and Clinical Response to Guselkumab in Participants With Active and Erosive Psoriatic Arthritis: Post hoc Analysis at Week 24 of the Phase 3b, Randomized, Double-blind, Placebo-controlled APEX Study

Christopher T Ritchlin, Proton Rahman, Laura C Coates, Alexa P Kollmeier, Yusang Jiang, Molly Caselton, Soumya D Chakravarty, Elizabeth Adamson, Karissa Lozenski, Arthur Kavanaugh, Philip J Mease


This document will be available on Sep 17th 2026

 

Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.

J&J Medical Connect

Connect with us

Connect with us

Would you like to clear and leave your conversation? Message history will be lost.